PRESS RELEASE Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Lo...
Fast Track is an FDA process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The FDA states the purpose of Fast Track to get important new drugs to the patient earlier.
Abstract title - A Randomized, Placebo-Controlled, Multicenter Proof-of-Concept (POC) Study to Assess the Safety and Efficacy of the Novel Allosteric AKT Inhibitor, VAD044, in Adults with Hereditary Hemorrhagic Telangiectasia (HHT)
Trial delivers positive results in first ever industry-led clinical trial in Hereditary Haemorrhagic Telangiectasia (HHT)
Vaderis is a biotechnology company focusing on treatment of rare and Orphan Diseases caused by Vascular Malformations